German clinical-stage immuno-oncology company Glycotope has appointed Dr Alfredo Zurlo as chief medical officer.
He joins the firm from Mologen AG, where he was its chief medical officer and a member of the Berlin-based biotech’s executive board.
Prior that Dr Zurlo held various positions at F Hoffmann La Roche and Roche SA, including senior international medical leader director oncology and medical director oncology.
Previous to his time at Roche he was a medical advisor for the European Organisation for the Research and Treatment of Cancer (EORTC).
Glycotope’s chief executive officer Paul Higham said: “We are delighted that Alfredo has decided to join Glycotope. He has an exceptionally strong background in oncology both in a clinical setting and within companies developing and marketing treatments for cancer.
“His experience in designing and managing clinical trials will be invaluable as we continue to advance our mature and growing pipeline of proprietary cancer therapies including our oncology lead PankoMab-GEX which is currently in phase IIb in ovarian cancer.“